{"product_id":"individual-participant-data-metaanalysis-9781119333722","title":"Individual Participant Data MetaAnalysis","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cp\u003e\u003ci\u003eIndividual Participant Data Meta-Analysis: A Handbook for Healthcare Research\u003c\/i\u003e provides a comprehensive introduction to the fundamental principles and methods that healthcare researchers need when considering, conducting or using individual participant data (IPD) meta-analysis projects. Written and edited by researchers with substantial experience in the field, the book details key concepts and practical guidance for each stage of an IPD meta-analysis project, alongside illustrated examples and summary learning points.\u003c\/p\u003e \u003cp\u003eSplit into five parts, the book chapters take the reader through the journey from initiating and planning IPD projects to obtaining, checking, and meta-analysing IPD, and appraising and reporting findings. The book initially focuses on the synthesis of IPD from randomised trials to evaluate treatment effects, including the evaluation of participant-level effect modifiers (treatment-covariate interactions). Detailed extension is then made to specialist top\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003c\/p\u003e\u003cp\u003eAcknowledgements xxiii\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1 Individual Participant Data Meta-analysis for Healthcare Research \u003c\/b\u003e\u003cb\u003e1\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eRichard D. Riley, Lesley A. Stewart, and Jayne F. Tierney\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1.1 Introduction 1\u003c\/p\u003e \u003cp\u003e1.2 What Is IPD and How Does It Differ from Aggregate Data? 1\u003c\/p\u003e \u003cp\u003e1.3 IPD Meta-analysis: A New Era for Evidence Synthesis 2\u003c\/p\u003e \u003cp\u003e1.4 Scope of This Book and Intended Audience 2\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart I Rationale, Planning, and Conduct \u003c\/b\u003e\u003cb\u003e7\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2 Rationale for Embarking on an IPD Meta-analysis Project \u003c\/b\u003e\u003cb\u003e9\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eJayne F. Tierney, Richard D. Riley, Catrin Tudur Smith, Mike Clarke, and Lesley A. Stewart\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2.1 Introduction 9\u003c\/p\u003e \u003cp\u003e2.2 How Does the Research Process Differ for IPD and Aggregate Data Meta-analysis Projects? 10\u003c\/p\u003e \u003cp\u003e2.3 What Are the Potential Advantages of an IPD Meta-analysis Project? 11\u003c\/p\u003e \u003cp\u003e2.4 What Are the Potential Challenges of an IPD Meta-Analysis Project? 14\u003c\/p\u003e \u003cp\u003e2.5 Empirical Evidence of Differences between Results of IPD and Aggregate Data Metaanalysis Projects 14\u003c\/p\u003e \u003cp\u003e2.6 Guidance for Deciding When IPD Meta-analysis Projects Are Needed to Evaluate Treatment Effects from Randomised Trials 15\u003c\/p\u003e \u003cp\u003e2.7 Concluding Remarks 19\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3 Planning and Initiating an IPD Meta-analysis Project \u003c\/b\u003e\u003cb\u003e21\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eLesley A. Stewart, Richard D. Riley, and Jayne F. Tierney\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3.1 Introduction 22\u003c\/p\u003e \u003cp\u003e3.2 Organisational Approach 22\u003c\/p\u003e \u003cp\u003e3.3 Developing a Project Scope 26\u003c\/p\u003e \u003cp\u003e3.4 Assessing Feasibility and ‘In Principle’ Support and Collaboration 26\u003c\/p\u003e \u003cp\u003e3.5 Establishing a Team with the Right Skills 29\u003c\/p\u003e \u003cp\u003e3.6 Advisory and Governance Functions 30\u003c\/p\u003e \u003cp\u003e3.7 Estimating How Long the Project Will Take 31\u003c\/p\u003e \u003cp\u003e3.8 Estimating the Resources Required 33\u003c\/p\u003e \u003cp\u003e3.9 Obtaining Funding 38\u003c\/p\u003e \u003cp\u003e3.10 Obtaining Ethical Approval 39\u003c\/p\u003e \u003cp\u003e3.11 Data-sharing Agreement 41\u003c\/p\u003e \u003cp\u003e3.12 Additional Planning for Prospective Meta-analysis Projects 41\u003c\/p\u003e \u003cp\u003e3.13 Concluding Remarks 43\u003c\/p\u003e \u003cp\u003e\u003cb\u003e4 Running an IPD Meta-analysis Project: From Developing the Protocol to Preparing Data for Meta-analysis \u003c\/b\u003e\u003cb\u003e45\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eJayne F. Tierney, Richard D. Riley, Larysa H.M. Rydzewska, and Lesley A. Stewart\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4.1 Introduction 46\u003c\/p\u003e \u003cp\u003e4.2 Preparing to Collect IPD 46\u003c\/p\u003e \u003cp\u003e4.3 Initiating and Maintaining Collaboration 57\u003c\/p\u003e \u003cp\u003e4.4 Obtaining IPD 59\u003c\/p\u003e \u003cp\u003e4.5 Checking and Harmonising Incoming IPD 62\u003c\/p\u003e \u003cp\u003e4.6 Checking the IPD to Inform Risk of Bias Assessments 66\u003c\/p\u003e \u003cp\u003e4.7 Assessing and Presenting the Overall Quality of a Trial 76\u003c\/p\u003e \u003cp\u003e4.8 Verification of Finalised Trial IPD 77\u003c\/p\u003e \u003cp\u003e4.9 Merging IPD Ready for Meta-analysis 77\u003c\/p\u003e \u003cp\u003e4.10 Concluding Remarks 80\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart I References \u003c\/b\u003e\u003cb\u003e81\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart II Fundamental Statistical Methods and Principles \u003c\/b\u003e\u003cb\u003e87\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e5 The Two-stage Approach to IPD Meta-analysis \u003c\/b\u003e\u003cb\u003e89\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eRichard D. Riley, Thomas P.A. Debray, Tim P. Morris, and Dan Jackson\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e5.1 Introduction 90\u003c\/p\u003e \u003cp\u003e5.2 First Stage of a Two-stage IPD Meta-analysis 90\u003c\/p\u003e \u003cp\u003e5.3 Second Stage of a Two-stage IPD Meta-analysis 106\u003c\/p\u003e \u003cp\u003e5.4 Meta-regression and Subgroup Analyses 120\u003c\/p\u003e \u003cp\u003e5.5 The \u003ci\u003eipdmetan \u003c\/i\u003eSoftware Package 121\u003c\/p\u003e \u003cp\u003e5.6 Combining IPD with Aggregate Data from non-IPD Trials 124\u003c\/p\u003e \u003cp\u003e5.7 Concluding Remarks 125\u003c\/p\u003e \u003cp\u003e\u003cb\u003e6 The One-stage Approach to IPD Meta-analysis \u003c\/b\u003e\u003cb\u003e127\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eRichard D. Riley and Thomas P.A. Debray \u003c\/i\u003e127\u003c\/p\u003e \u003cp\u003e6.1 Introduction 128\u003c\/p\u003e \u003cp\u003e6.2 One-stage IPD Meta-analysis Models Using Generalised Linear Mixed Models 129\u003c\/p\u003e \u003cp\u003e6.3 One-stage Models for Time-to-event Outcomes 152\u003c\/p\u003e \u003cp\u003e6.4 One-stage Models Combining Different Sources of Evidence 159\u003c\/p\u003e \u003cp\u003e6.5 Reporting of One-stage Models in Protocols and Publications 162\u003c\/p\u003e \u003cp\u003e6.6 Concluding Remarks 162\u003c\/p\u003e \u003cp\u003e\u003cb\u003e7 Using IPD Meta-analysis to Examine Interactions between Treatment Effect and Participant-level Covariates \u003c\/b\u003e\u003cb\u003e163\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eRichard D. Riley and David J. Fisher\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e7.1 Introduction 164\u003c\/p\u003e \u003cp\u003e7.2 Meta-regression and Its Limitations 166\u003c\/p\u003e \u003cp\u003e7.3 Two-stage IPD Meta-analysis to Estimate Treatment-covariate Interactions 168\u003c\/p\u003e \u003cp\u003e7.4 The One-stage Approach 174\u003c\/p\u003e \u003cp\u003e7.5 Combining IPD and non-IPD Trials 181\u003c\/p\u003e \u003cp\u003e7.6 Handling of Continuous Covariates 184\u003c\/p\u003e \u003cp\u003e7.7 Handling of Categorical or Ordinal Covariates 191\u003c\/p\u003e \u003cp\u003e7.8 Misconceptions and Cautions 191\u003c\/p\u003e \u003cp\u003e7.9 Is My Identified Treatment-covariate Interaction Genuine? 195\u003c\/p\u003e \u003cp\u003e7.10 Reporting of Analyses of Treatment-covariate Interactions 196\u003c\/p\u003e \u003cp\u003e7.11 Can We Predict a New Patient’s Treatment Effect? 196\u003c\/p\u003e \u003cp\u003e7.11.1 Linking Predictions to Clinical Decision Making 198\u003c\/p\u003e \u003cp\u003e7.12 Concluding Remarks 198\u003c\/p\u003e \u003cp\u003e\u003cb\u003e8 One-stage versus Two-stage Approach to IPD Meta-analysis: Differences and Recommendations \u003c\/b\u003e\u003cb\u003e199\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eRichard D. Riley, Danielle L. Burke, and Tim Morris\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e8.1 Introduction 200\u003c\/p\u003e \u003cp\u003e8.2 One-stage and Two-stage Approaches Usually Give Similar Results 200\u003c\/p\u003e \u003cp\u003e8.3 Ten Key Reasons Why One-stage and Two-stage Approaches May Give Different Results 203\u003c\/p\u003e \u003cp\u003e8.4 Recommendations and Guidance 216\u003c\/p\u003e \u003cp\u003e8.5 Concluding Remarks 217\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart II References \u003c\/b\u003e\u003cb\u003e219\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart III Critical Appraisal and Dissemination \u003c\/b\u003e\u003cb\u003e237\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e9 Examining the Potential for Bias in IPD Meta-analysis Results \u003c\/b\u003e\u003cb\u003e239\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eRichard D. Riley, Jayne F. Tierney, and Lesley A. Stewart\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e9.1 Introduction 240\u003c\/p\u003e \u003cp\u003e9.2 Publication and Reporting Biases of Trials 240\u003c\/p\u003e \u003cp\u003e9.3 Biased Availability of the IPD from Trials 244\u003c\/p\u003e \u003cp\u003e9.4 Trial Quality (risk of bias) 247\u003c\/p\u003e \u003cp\u003e9.5 Other Potential Biases Affecting IPD Meta-analysis Results 248\u003c\/p\u003e \u003cp\u003e9.6 Concluding Remarks 251\u003c\/p\u003e \u003cp\u003e\u003cb\u003e10 Reporting and Dissemination of IPD Meta-analyses \u003c\/b\u003e\u003cb\u003e253\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eLesley A. Stewart, Richard D. Riley, and Jayne F. Tierney\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e10.1 Introduction 253\u003c\/p\u003e \u003cp\u003e10.2 Reporting IPD Meta-analysis Projects in Academic Reports 254\u003c\/p\u003e \u003cp\u003e10.3 Additional Means of Disseminating Findings 266\u003c\/p\u003e \u003cp\u003e10.4 Concluding Remarks 270\u003c\/p\u003e \u003cp\u003e\u003cb\u003e11 A Tool for the Critical Appraisal of IPD Meta-analysis Projects (CheckMAP) \u003c\/b\u003e\u003cb\u003e271\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eJayne F. Tierney, Lesley A. Stewart, Claire L. Vale, and Richard D. Riley\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e11.1 Introduction 271\u003c\/p\u003e \u003cp\u003e11.2 The CheckMAP Tool 272\u003c\/p\u003e \u003cp\u003e11.3 Was the IPD Meta-analysis Project Done within a Systematic Review Framework? 272\u003c\/p\u003e \u003cp\u003e11.4 Were the IPD Meta-analysis Project Methods Pre-specified in a Publicly Available Protocol? 274\u003c\/p\u003e \u003cp\u003e11.5 Did the IPD Meta-analysis Project Have a Clear Research Question Qualified by Explicit Eligibility Criteria? 276\u003c\/p\u003e \u003cp\u003e11.6 Did the IPD Meta-analysis Project Have a Systematic and Comprehensive Search Strategy? 276\u003c\/p\u003e \u003cp\u003e11.7 Was the Approach to Data Collection Consistent and Thorough? 277\u003c\/p\u003e \u003cp\u003e11.8 Were IPD Obtained from Most Eligible Trials and Their Participants? 277\u003c\/p\u003e \u003cp\u003e11.9 Was the Validity of the IPD Checked for Each Trial? 278\u003c\/p\u003e \u003cp\u003e11.10 Was the Risk of Bias Assessed for Each Trial and Its Associated IPD? 27811.10.1 Was the Randomisation Process Checked Based on IPD? 278\u003c\/p\u003e \u003cp\u003e11.11 Were the Methods of Meta-analysis Appropriate? 280\u003c\/p\u003e \u003cp\u003e11.12 Concluding Remarks 283\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart III References \u003c\/b\u003e\u003cb\u003e285\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart IV Special Topics in Statistics \u003c\/b\u003e\u003cb\u003e291\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e12 Power Calculations for Planning an IPD Meta-analysis \u003c\/b\u003e\u003cb\u003e293\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eRichard D. Riley and Joie Ensor\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e12.1 Introduction 294\u003c\/p\u003e \u003cp\u003e12.2 Motivating Example: Power of a Planned IPD Meta-analysis of Trials of Interventions to Reduce Weight Gain in Pregnant Women 295\u003c\/p\u003e \u003cp\u003e12.3 The Contribution of Individual Trials Toward Power 301\u003c\/p\u003e \u003cp\u003e12.4 The Impact of Model Assumptions on Power 302\u003c\/p\u003e \u003cp\u003e12.5 Extensions 305\u003c\/p\u003e \u003cp\u003e12.6 Concluding Remarks 309\u003c\/p\u003e \u003cp\u003e\u003cb\u003e13 Multivariate Meta-analysis Using IPD \u003c\/b\u003e\u003cb\u003e311\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eRichard D. Riley, Dan Jackson, and Ian R. White\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e13.1 Introduction 312\u003c\/p\u003e \u003cp\u003e13.2 General Two-stage Approach for Multivariate IPD Meta-analysis 314\u003c\/p\u003e \u003cp\u003e13.3 Application to an IPD Meta-analysis of Anti-hypertensive Trials 329\u003c\/p\u003e \u003cp\u003e13.4 Extension to Multivariate Meta-regression 333\u003c\/p\u003e \u003cp\u003e13.5 Potential Limitations of Multivariate Meta-analysis 334\u003c\/p\u003e \u003cp\u003e13.6 One-stage Multivariate IPD Meta-analysis Applications 337\u003c\/p\u003e \u003cp\u003e13.7 Special Applications of Multivariate Meta-analysis 340\u003c\/p\u003e \u003cp\u003e13.8 Concluding Remarks 346\u003c\/p\u003e \u003cp\u003e\u003cb\u003e14 Network Meta-analysis Using IPD \u003c\/b\u003e\u003cb\u003e347\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eRichard D. Riley, David M. Phillippo, and Sofia Dias\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e14.1 Introduction 348\u003c\/p\u003e \u003cp\u003e14.2 Rationale and Assumptions for Network Meta-analysis 348\u003c\/p\u003e \u003cp\u003e14.3 Network Meta-analysis Models Assuming Consistency 350\u003c\/p\u003e \u003cp\u003e14.4 Ranking Treatments 357\u003c\/p\u003e \u003cp\u003e14.5 How Do We Examine Inconsistency between Direct and Indirect Evidence? 359\u003c\/p\u003e \u003cp\u003e14.6 Benefits of IPD for Network Meta-analysis 361\u003c\/p\u003e \u003cp\u003e14.7 Combining IPD and Aggregate Data in Network Meta-analysis 365\u003c\/p\u003e \u003cp\u003e14.8 Further Topics 370\u003c\/p\u003e \u003cp\u003e14.9 Concluding Remarks 372\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart IV References \u003c\/b\u003e\u003cb\u003e375\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart V Diagnosis, Prognosis and Prediction \u003c\/b\u003e\u003cb\u003e387\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e15 IPD Meta-analysis for Test Accuracy Research \u003c\/b\u003e\u003cb\u003e389\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eRichard D. Riley, Brooke Levis, and Yemisi Takwoingi \u003c\/i\u003e389\u003c\/p\u003e \u003cp\u003e15.1 Introduction 390\u003c\/p\u003e \u003cp\u003e15.2 Motivating Example: Diagnosis of Fever in Children Using Ear Temperature 394\u003c\/p\u003e \u003cp\u003e15.3 Key Steps Involved in an IPD Meta-analysis of Test Accuracy Studies 397\u003c\/p\u003e \u003cp\u003e15.4 IPD Meta-analysis of Test Accuracy at Multiple Thresholds 410\u003c\/p\u003e \u003cp\u003e15.5 IPD Meta-analysis for Examining a Test’s Clinical Utility 414\u003c\/p\u003e \u003cp\u003e15.6 Comparing Tests 418\u003c\/p\u003e \u003cp\u003e15.7 Concluding Remarks 420\u003c\/p\u003e \u003cp\u003e\u003cb\u003e16 IPD Meta-analysis for Prognostic Factor Research \u003c\/b\u003e\u003cb\u003e421\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eRichard D. Riley, Karel G.M. Moons, and Thomas P.A. Debray\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e16.1 Introduction 422\u003c\/p\u003e \u003cp\u003e16.2 Potential Advantages of an IPD Meta-analysis 424\u003c\/p\u003e \u003cp\u003e16.3 Key Steps Involved in an IPD Meta-analysis of Prognostic Factor Studies 427\u003c\/p\u003e \u003cp\u003e16.4 Software 444\u003c\/p\u003e \u003cp\u003e16.5 Concluding Remarks 444\u003c\/p\u003e \u003cp\u003e\u003cb\u003e17 IPD Meta-analysis for Clinical Prediction Model Research \u003c\/b\u003e\u003cb\u003e447\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eRichard D. Riley, Kym I.E. Snell, Laure Wynants, Valentijn M.T. de Jong, Karel G.M. Moons, and Thomas P.A. Debray\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e17.1 Introduction 448\u003c\/p\u003e \u003cp\u003e17.2 IPD Meta-analysis for Prediction Model Research 448\u003c\/p\u003e \u003cp\u003e17.3 External Validation of an Existing Prediction Model Using IPD Meta-analysis 455\u003c\/p\u003e \u003cp\u003e17.4 Updating and Tailoring of a Prediction Model Using IPD Meta-analysis 470\u003c\/p\u003e \u003cp\u003e17.5 Comparison of Multiple Existing Prediction Models Using IPD Meta-analysis 472\u003c\/p\u003e \u003cp\u003e17.6 Using IPD Meta-analysis to Examine the Added Value of a New Predictor to an Existing Prediction Model 478\u003c\/p\u003e \u003cp\u003e17.7 Developing a New Prediction Model Using IPD Meta-analysis 479\u003c\/p\u003e \u003cp\u003e17.8 Examining the Utility of a Prediction Model Using IPD Meta-analysis 491\u003c\/p\u003e \u003cp\u003e17.9 Software 494\u003c\/p\u003e \u003cp\u003e17.10 Reporting 495\u003c\/p\u003e \u003cp\u003e17.11 Concluding Remarks 495\u003c\/p\u003e \u003cp\u003e\u003cb\u003e18 Dealing with Missing Data in an IPD Meta-analysis \u003c\/b\u003e\u003cb\u003e499\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eThomas Debray, Kym I.E. Snell, Matteo Quartagno, Shahab Jolani, Karel G.M. Moons, and Richard D. Riley \u003c\/i\u003e499\u003c\/p\u003e \u003cp\u003e18.1 Introduction 500\u003c\/p\u003e \u003cp\u003e18.2 Motivating Example: IPD Meta-analysis Validating Prediction Models for Risk of Preeclampsia in Pregnancy 500\u003c\/p\u003e \u003cp\u003e18.3 Types of Missing Data in an IPD Meta-analysis 502\u003c\/p\u003e \u003cp\u003e18.4 Recovering Actual Values of Missing Data within IPD 502\u003c\/p\u003e \u003cp\u003e18.5 Mechanisms and Patterns of Missing Data in an IPD Meta-analysis 502\u003c\/p\u003e \u003cp\u003e18.6 Multiple Imputation to Deal with Missing Data in a Single Study 506\u003c\/p\u003e \u003cp\u003e18.7 Ensuring Congeniality of Imputation and Analysis Models 509\u003c\/p\u003e \u003cp\u003e18.8 Dealing with Sporadically Missing Data in an IPD Meta-analysis by Applying Multiple Imputation for Each Study Separately 509\u003c\/p\u003e \u003cp\u003e18.9 Dealing with Systematically Missing Data in an IPD Meta-analysis Using a Bivariate Metaanalysis of Partially and Fully Adjusted Results 511\u003c\/p\u003e \u003cp\u003e18.10 Dealing with Both Sporadically and Systematically Missing Data in an IPD Meta-analysis Using Multilevel Modelling 514\u003c\/p\u003e \u003cp\u003e18.11 Comparison of Methods and Recommendations 521\u003c\/p\u003e \u003cp\u003e18.12 Software 523\u003c\/p\u003e \u003cp\u003e18.13 Concluding Remarks 524\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart V References \u003c\/b\u003e\u003cb\u003e525\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eIndex 000\u003c\/p\u003e","brand":"John Wiley \u0026 Sons Inc","offers":[{"title":"Default Title","offer_id":48866392572247,"sku":"9781119333722","price":62.65,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9781119333722.jpg?v=1722278434","url":"https:\/\/bookcurl.com\/products\/individual-participant-data-metaanalysis-9781119333722","provider":"Book Curl","version":"1.0","type":"link"}